StemCell Therapy

Biotechnology Reagents Market report offers one of the best solutions to know the trends and opportunities in healthcare industry. The industry analysis report offers broader perspective of the market place with its comprehensive market insights and analysis. This market research report contains lot of features to offer for healthcare industry which includes general market conditions, trends, inclinations, key players, opportunities, and geographical analysis. What is more, global Biotechnology Reagents market document provides superior market perspective in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions or behaviors.

The first class Biotechnology Reagents business report contains top to bottom analysis and estimation of various market related factors that are incredibly crucial for better decision making. Competitive analysis has been carried out in this business report for the major players in the market which supports businesses take better moves for enhancing their product and sales. Besides, Biotechnology Reagents market survey report takes into consideration several industry verticals such as company profile, contact details of manufacturer, product specifications, geographical scope, production value, market structures, recent developments, revenue analysis, market shares and possible sales volume of the company.

Download Exclusive Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-biotechnology-reagents-market&AZ

Key Market Players mentioned in this report:Abbott, Agilent Technologies Inc., Danaher, BD, Bio-Rad Laboratories Inc., General Electric, bioMrieux SA, LONZA, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Hoefer, Inc., Meridian Bioscience, Inc., PerkinElmer

Market Analysis and Insights: Global Biotechnology Reagents Market:

The biotechnology reagents market is expected to gain market growth in the forecast period of 2022 to 2027. Data Bridge Market Research analyses that the market is growing with the CAGR of 11.7% in the forecast period of 2022 to 2027 and is expected to reach USD 10.37 billion by 2027. The growing number of clinical trials will help in escalating the growth of the biotechnology reagents market.

This Biotechnology Reagents market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research Biotechnology Reagents market contact us for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

To know more details, visit in depth study Report @ https://www.databridgemarketresearch.com/reports/global-biotechnology-reagents-market?aZ

Biotechnology Reagents Market Country Level Analysis:

The Biotechnology Reagents market is segmented on the basis of product type, application and end user.

The countries covered in the Biotechnology Reagents market report are the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Competitive Landscape and Biotechnology Reagents Market Share Analysis:

The Biotechnology Reagents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Biotechnology Reagents market.

Table Of Contents: Global Biotechnology Reagents Market

1 Introduction2 Market Segmentation3 Market Overview4 Executive Summary5 Premium Insights6 Global Biotechnology Reagents Market, By Type7 Global Biotechnology Reagents Market, By Tumor Type8 Global Biotechnology Reagents Market, By Application9 Global Biotechnology Reagents Market, By End User10 Global Biotechnology Reagents Market, By Geography11 Global Biotechnology Reagents Market, Company Landscape12 Company Profiles13 Related Reports

Check Complete Table of Contents with List of Table and Figures @ https://www.databridgemarketresearch.com/toc/?dbmr=global-biotechnology-reagents-market&Az

The key questions answered in Biotechnology Reagents Market report are:

Key points covered in the report:

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email corporatesales@databridgemarketresearch.com

See the rest here:
Biotechnology Reagents Trends, Market Share, Industry Size, Growth, Opportunities and Forecast to 2028 The Oxford Spokesman - The Oxford Spokesman

One of the next big shifts in patient care will be precision medicine will be"an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment and lifestyle for each person," as the Precision Medicine Initiative describes it.

For physicians and researchersthis means predicting more accurately which treatment and prevention strategies for a particular disease will work in particular groups of people.

This is completely different from the traditional one-size-fits-all approach, in which treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.

What does this mean for healthcare and health IT? A lot of new challenges. Because precision medicine and genomics generate massive volumes of varied and granular data, new approaches to data storage and exchangeand new designs for electronic health records,for example, may be required. Physician education and patient communication are two other areas that will demand attention

Some advanced healthcare provider organizations, such as large academic medical centers,are already well-advanced in their precision medicine efforts. But most providers are still early in the journey, if they're attempting it at all. But many are preparing today for what many think will be the next step in the evolution of healthcare.

This story, focused on precision medicine and other emerging technologies, is the sixth and final installment in Healthcare IT News' feature series, "Health IT Investment: The Next Five Years."

The series offers interviews with primarily CIOs to learn from them the path forward through the priorities they set with their investments in six categories: AI and machine learning; interoperability; telehealth, connected health and remote patient monitoring; cybersecurity; electronic health records and population health; and precision medicine and other emerging technologies. Click here to access all the features.

The six health IT leaders discussing their plans for the next five years in this sixth and final installment in the series include:

Precision medicine has been an organizational priority for UPMC for more than a decade, and it has an ambitious vision of using it to provide better, more personalized care and improved outcomes for patients.

"Through these efforts, we aim to create new insights into the drivers of health and disease to allow the discovery of innovative therapies and models of care, while also lowering the cost of care by avoiding diagnostic delays and therapeutic dead ends," said Kleinz of UPMC.

"As one of the largest integrated healthcare delivery and insurance organizations, UPMC has the scale, capabilities and ambition to lead the discovery, assessment and clinical deployment of impactful precision medicine approaches," he continued.

Dr. Matthias J. Kleinz, UPMC Enterprises

"Our efforts are led by the Institute for Precision Medicine, which was established in 2014 in collaboration with our academic research partner, the University of Pittsburgh."

The mission for the institute is to accelerate translational and clinical research in precision medicine and to deliver the most advanced prediction and treatment of disease, tailored to an individual's unique circumstances, history and condition.

"In this context, we have and will continue to make significant investments in established molecular and genomic tests [and]emerging proteomic, metabolomic, and microbiome assay technology, and drive the discovery of highly personalized precision therapeutic approaches, including cell, gene and regenerative medicines," Kleinz explained.

Investment in deployment and development of novel technologies is an important pillar inunlocking the value of precision medicine.

UPMC has made a number of significant initial investments in the following areas, Kleinz noted, and is continuing to evaluate new opportunities:

"UPMC's leadership strongly supports this vision and already has invested heavily in the implementation of precision medicine," he said. "The appropriate use of precision medicine approaches benefits first and foremost our patients, but also supports our providers as they deliver care across the UPMC system.

"The tangible benefits are streamlined clinical workflows, improved patient outcomes, and the potential to optimize resource allocation and reduce the long-term cost of care," he continued.

"We are dedicated to continuing the aggressive rollout of precision medicine, both through internal efforts and increasingly through creative partnerships with industry, such as our partnership with proteomics company Somalogic."

Sanford Health believes precision medicine will be the future of healthcare, so it continues to make significant investments in this space.

"Leveraging machine learning and high computational power to analyze data sets containing genetic, clinical and socioeconomic data will not only help design the best personalized treatment for our patients, but also will help identify those patients or patient populations that would benefit most from early screening and interventions to prevent disease," said Hocks of Sanford Health.

Matt Hocks, Sanford Health

"Precision medicine will allow us to concentrate our efforts on prevention and early screening, diagnosis, and care that will help keep our patients healthy and thriving for generations to come," he added. "Cancer care and chronic disease management are burdensome to patients, communities and health systems. Concentrating resources to prevent these conditions will benefit us all."

Mobile health is an area of health IT that has been emerging in recent years. The same with remote patient monitoring, which has especially gained ground during the COVID-19 pandemic. Virginia Hospital Center is on top of both.

"Virginia Hospital Center does not view itself as cutting-edge when it comes to technology," Mistretta said. "It considers itself more of a fast, early adopter of new technology it believes may provide an advantage to its patients.

"We are extremely patient-focused, so many of our investments moving forward are going to be in that realm," he continued. "We will be investing in hospital-at-home and remote patient monitoring features in depth, along with other patient engagement functions to empower our population and maintain low-touch care to minimize costs."

Mike Mistretta, Virginia Hospital Center

Mobility is in demand by patients, so connecting through web and app technologies will be a high priority, he added.

"We need to make care convenient for patients and provide care on their terms," he observed. "In our Northern Virginia/D.C. market, we hear about this frequently due to traffic and distance considerations."

Thus the development of pilot programs like the organization's OB Connect, where patients followed for maternity care are issued home equipment, post resultsand are able to skip the office if everything is within expected limits. Mistretta believes this kind of technology will permeate the market.

"These types of technologies will be required to sustain significant growth for health systems," he said. "Combined with the effective use of data to produce appropriate metrics, we should be able to pinpoint more specific markets and what treatments produce more effective outcomes.

"It also is the only way we will be able to meet the significant demands that will be placed on the care system with the shortage of nursing and primary care resources predicted to hit in the coming years," he added. "We simply will not be able to continue to experience the same results and levels of treatment enjoyed today as the population grows and ages without providing increased care outside the walls of our traditional organizational structures."

Leadership buy-in on a different approach will take some time, but with successes along the way (and supporting data to reinforce), healthcare organizations will be able to achieve what will be needed, he said.

Providence pledged to invest $50 million over five years in health equity. Here is a recap of how it invested in year one.

Elsewhere, Moore is concerned with the internet of things.

"The internet of things is it it's smart devices," he said. "We may give our patients smart devices that sit in our care delivery environments, and have the telemetry information, and go into our big data model. Because that's how we're really going to make these machine learning and artificial intelligence models shine.

B.J. Moore, Providence

"We in healthcare say big data, but until you're working with streams of data, it's not really big data, it's just large data warehouses," he continued. "So getting that remote care delivery data is important, like a temperature four times a day, or real-time streaming of oxygen or heart data."

Moore believes the IoT and the streams of data it can provide are things healthcare executives should be talking about more. "It's all about data volumes: The bigger the volume, the better," he said.

Regenstrief is in the process of developing tools and processes to identify bias in algorithms to improve health equity, said Grannis of Regenstrief Institute.

"As AI becomes more ubiquitous, researchers, clinicians, health systems, industry, government and others must be wary of unintended consequences," he stated. "Our research scientists are working on best practices as well as novel analytical tools to regularly monitor for bias in algorithms, a process Regenstrief and CEO Dr. Peter Emb have coined "algorithmovigilance."

"Over the next five years, Regenstrief will be working with individuals and organizations around the world to implement," he added.

Dr. Shaun Grannis, Regenstrief Institute

Regenstrief also is investing in the broader ecosystem required to sustain advanced AI and machine learning methods. In the same way that clinical decision-makers, including physicians and other care providers, undergo regular training updates and certification due to healthcare's evolving nature and potential for bias, advanced algorithms will need frequent updates and certification to minimize bias and or errors, Grannis said.

Frameworks for overseeing algorithms and analytics are nascent.Developing and evaluating approaches to accurately and efficiently monitor AI and machine learning will become increasingly important in the future of healthcare analytics, he added.

"We also are investing in patient ergonomics the application of human factors,engineering and psychology to the design and evaluation of patient-facing technology to enhance delivery of healthcare," he explained.

"Institute scientists are using user-centered design to create apps that help informal caregivers provide care for their loved ones with Alzheimer's and other chronic conditions. Other apps are exploring the benefits of specific diets and brain-stimulating games."

Babachicos of South Shore Health believes tools that assist patients with care navigation will allow for a more improved and directed patient experience.

"These tools combined with the next-generation call centers also known as patient access centers can be accessed 24/7 by patients looking for care options and direct patients to the right place at the right time for their care needs," she explained. "These patient access centers will use multichannel options such as text, voice and chat while allowing patients to perform many self-service functions, as well.

Cara Babachicos, South Shore Health

"These patient access centers might also be staffed by care navigators for a more human connection when necessary," she concluded. "The same centers could potentially deliver virtual visits/consults, as well as potentially manage patient medications and vitals for subscribed patients in the community."

Twitter:@SiwickiHealthITEmail the writer:bsiwicki@himss.orgHealthcare IT News is a HIMSS Media publication.

The rest is here:
CIOs' 5-year plans for precision medicine and emerging technologies - Healthcare IT News

MONTPELLIER, France--(BUSINESS WIRE)--SeqOne Genomics, provider of next genomic analysis solutions for personalized medicine today announced a Series A funding round of 20M.

The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease.

The company will intensify investments in the development of its genomic-aware data lake to improve the use of big data and machine learning approaches in genomic analysis with the aim of better addressing the fast-evolving needs of molecular biology labs that provide genomic analysis in clinical routine environments, as well as to biopharma companies developing new therapies.

SeqOnes cloud-based solution manages the entire genomic analysis process from raw data to final report presented to clinicians. The solutions end-to-end approach affords better analytic performance, high levels of traceability and improved operational efficiency and has already been adopted by a score of hospitals and central labs and biopharmas as well as spawning partnerships with leading manufacturers of genomics analysis hardware and reagents.

Nicolas Philippe, Ph.D., Co-founder and CEO of SeqOne Genomics stated We are extremely happy to have closed this round with leading investors who bring extensive experience in deep-tech, healthcare and biotherapy and who share our vision of building SeqOne into a global leader in personalized medicine. The funding will give us the resources we need to enhance and commercialize our solution to make genomic analysis more accessible and affordable so that each patient can benefit from personalized medicine recommandations.

The genomics analysis market is experiencing exponential growth driven by the needs of personalized medicine. With the rapid expansion in the available genomic-linked treatments, the complexity of treatment interactions, and the staggering volume of biological and medical data to be factored into each medical decision, biologists and doctors must have access to reliable and actionable analyses in real-time, stated Fabien Collangettes, Director at Omnes. We were particularly impressed by SeqOnes innovative technological approach that enables improved accuracy of genomic test while reducing turnaround time and cost, thus delivering a key competitive advantage in this fast-growing market.

With the closing of this round, SeqOnes board of directors will be: Sacha Loiseau, Ph.D. independent board member and Chairman of the Board, Fabien Collangettes, Director at Omnes, Yoann Bonnamour, Investment Manager at Merieux Equity Partners, Marc Rougier, Partner at Elaia, Nicolas Philippe, co-founder and CEO of SeqOne Genomics and Jean-Marc Holder, Co-founder and Chief Strategy and Innovation officer of SeqOne Genomics.

This new funding round brings the total amount raised by SeqOne Genomics since its founding in 2017 to 23M.

The company currently employs over 40 staff, primarily experts in genomic medicine, data science, bioinformatics, software development and regulatory compliance / quality assurance. It plans to double its staff within the year to execute its ambitious plans.

Advisors:

Legal:Anthony Beauquier - LSF AdvisoryJones Day - Jean-Gabriel Griboul and Hortense FouillandMarket intelligence : Clara Niarfeix Alcimed

Intellectual property: Claire Verschelde, PhD ICOSA

Financial due diligence : Crowe HAF Maxime Hazim and Julien Latrubesse

About SeqOne Genomics

SeqOne Genomics offers high performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company's proprietary GeniOS genomics operating system to dramatically reduce turnaround times and costs while delivering a comprehensive and actionable insights for personalised medicine. The company has won numerous awards including the iLab award and the ARC cancer foundations Hlne Stark prize.Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club.

Web: https://seqone.com Direct link to this release: https://seqone.com/seriesa

About Elaia

For more information: http://www.elaia.com @Elaia_Partners

About IRDI Capital Investissement

Learn more: https://www.irdi.fr/

About Merieux Equity Partners

For more precision: http://www.merieux-partners.com

About Omnes

For more precision: http://www.omnescapital.com

About Software Club

For more precision: softwareclub.io

Go here to read the rest:
SeqOne Genomics Closes 20M Series a to Accelerate the Deployment of Its Genomic Medicine Platform - Business Wire

BUFFALO, N.Y. A joint study conducted by researchers at the University at Buffalo and the University of California, Los Angeles is revealing for the first time that behavioral self-management of irritable bowel syndrome (IBS), a painful and common gastrointestinal disorder, can fundamentally change the gut microbiome. It is the first to show how cognitive behavioral therapy can teach patients information-processing skills that address the biological roots of their GI symptoms.

This work demonstrates that teaching people how to think more flexibly in specific situations can reduce the physical tension and stress that can disrupt brain-gut interactions and crank up symptoms, said Jeffrey M. Lackner, PsyD, co-senior author on the paper, professor in the Department of Medicine and chief of the Division of Behavioral Medicine in the Jacobs School of Medicine and Biomedical Sciences at UB.

Published late last year in the journal Microbiome, this study, conceived by an interdisciplinary UB team, shows how a non-drug, non-dietary treatment for IBS induces changes in brain function and in the microbiome by normalizing ways of processing information, Lackner explained.

These results will have a dramatic impact on understanding a gastrointestinal disease that has a significant public health burden, he said. This is paradigm-shifting for how we understand the role of the microbiome and therapeutics that can modify its composition to treat and prevent disease.

Emeran A. Mayer, MD, an internationally known expert on the interactions between the digestive and nervous systems, is co-senior author on the paper. He is a professor in the David Geffen School of Medicine at UCLA and executive director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience.

"Dr. Lackners collaborative project with UCLA is an important breakthrough in the understanding of how cognitive behavioral therapy can alter brain-gut interaction to provide relief for IBS patients, saysAllison Brashear, MD, UBs vice president for health sciences and dean of theJacobs School. This studys translational research provides new hope for those afflicted with this debilitating disease.

The study was funded by grants from the National Institute of Diabetes and Digestive and Kidney Diseases to Lackner and Mayer, UBs Office of the Vice President for Research and Economic Development and UBs Genome, Environment and Microbiome (GEM) Community of Excellence.

The findings are the first to demonstrate that a specific type of cognitive behavioral therapy developed at UB that teaches information-processing skills can modulate key components of the brain-gut-microbiome axis in some of the most severe IBS patients, said Lackner.

Learning-based treatments

We know that the gut microbiome is a key to regulating brain-gut interactions and plays a role in overall human health from metabolism to immunity. We also know learning-based treatments like cognitive behavioral therapy are some of the most robust treatments of any kind for what is the most prevalent GI (gastrointestinal) disease, even when they are home-based delivered with minimal doctor involvement, said Lackner.

What we didnt know is how those two facts interact, said Lackner. We didnt know whether symptom relief following CBT depends on the microbiome environment to achieve its effects.

This study is important because it reveals a precise microbiome signature that distinguishes patients who respond positively to a drug-free treatment and those who dont, and that signature corresponds with objective changes in brain function, he added.

The fact that we see patient-reported GI symptom improvements that correspond with objective biological changes in the microbiome and brain function is pretty remarkable given that we focused on a low-intensity, home-based behavioral treatment and not medical therapies like probiotics, prebiotics, postbiotics, antibiotics, and fecal microbiota transplantation known to manipulate our microbiome, Lackner said.

Eighty-four IBS patients were recruited from the parent CBT trial the Irritable Bowel Syndrome Outcome Study, a landmark, National Institutes of Health-funded clinical trial led by Lackner that has transformed the way IBS is understood and treated.

The 84 participants underwent neuroimaging and detailed clinical assessment at clinical sites at UB and Northwestern University. UB also collected microbiome data through fecal sampling from 34 of the patients.

Eligible patients were randomized to receive 10 sessions of clinic-based CBT or four sessions of largely home-based CBT with minimal therapist contact over a 10-week acute phase. Both treatments were developed at UB.

Boundary-breaking translational research

This trial was enormously complex in that we collected symptom data across different sites at pre-treatment and post-treatment, said Lackner, who sees patients at the Behavioral Medicine Clinic at UBMD Internal Medicine. Because we were also collecting biological data at multiple times, it required a high level of precision and project management unique among major research centers. It really speaks to our divisions capacity to support boundary-breaking, novel translational research with high impact potential.

UB partnered with the David Geffen School of Medicine at UCLA and the G. Oppenheimer Center for Neurobiology of Stress and Resilience at UCLA.

All that data had to be expertly analyzed and that is where we were able to draw from the expertise of our long-standing collaborators at UCLA, experts in microbiome and imaging research, Lackner says.

UB developed the treatment, delivered it and collected data, while UCLA analyzed gut microbiome and neuroimaging data.

It is a great example of team science between two outstanding research facilities with unique synergies, Lackner says. Theres a lot of reasons why this type of study hasnt been done up to now, but we were able to leverage our unique clinical expertise and our clinical research infrastructure and UCLAs expertise.

Of the 84 participants in the trial, 58 were classified as CBT responders and 26 were classified as non-responders.

While there were small pre-treatment differences between brain network connectivity for responders and non-responders, the significant difference was how much the connectivity changed after treatment.

Responders showed greater baseline connectivity than non-responders between the central autonomic network and the emotional regulation network, according to the study.

Lackner said that the findings raise the possibility that CBT-responsive IBS patients can be identified in clinical practice using microbial biomarkers, before less effective treatments are initiated at great expense to the patient and health care system.

The pattern of data may explain normal versus abnormal gut function and just how the brain-gut can influence symptoms and the relief of them, Lackner says. Larger studies are needed to characterize the functional correlates of gut microbial changes and to identify distinct subtypes of IBS patients for whom brain- and gut-directed therapies are most effective.

This is an example of science moving away from a one-size-fits-all brand of medicine toward a more personalized medicine approach driven by translational research.

Jonathan P. Jacobs, MD, PhD, and Arpana (Annie) Gupta, PhD, both of the David Geffen School of Medicine at UCLA and the G. Oppenheimer Center for Neurobiology of Stress and Resilience at UCLA, are the studys co-first authors.

Co-authors from the Jacobs Schools Division of Behavioral Medicine are:

Rebecca S. Firth, division administrator and research coordinator.

Gregory D. Gudleski, PhD, research assistant professor.

Other co-authors are from the following institutions:

David Geffen School of Medicine at UCLA.

G. Oppenheimer Center for Neurobiology of Stress and Resilience at UCLA.

Imaging Genetics Center, Mark and Mary Stevens Institute for Neuroimaging and Informatics, Keck School of Medicine at University of Southern California.

Read more here:
Study: In IBS patients, cognitive behavioral therapy modulates the brain-gut microbiome and helps relieve symptoms - UB News Center

[93 Pages Report] Digital Genome Market Insights 2022 This report contains market size and forecasts of Digital Genome in United States, including the following market information:

United States Digital Genome Market Revenue, 2016-2021, 2022-2027, (USD millions)

United States top five Digital Genome companies in 2020 (%)

The global Digital Genome market size is expected to growth from USD 6963.3 million in 2020 to USD 10930 million by 2027; it is expected to grow at a CAGR of 6.2% during 2021-2027.

The United States Digital Genome market was valued at USD million in 2020 and is projected to reach USD million by 2027, at a CAGR of % during the forecast period.

The Research has surveyed the Digital Genome Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19492806

Leading key players of Digital Genome Market are

Digital Genome Market Type Segment Analysis (Market size available for years 2022-2027, Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2027): Sequencing Services, Sequencing Instruments, Sequencing Consumables, Bioinformatics, Sample Preparation Kits and Reagents

Regions that are expected to dominate the Digital Genome market are North America, Europe, Asia-Pacific, South America, Middle East and Africa and others

If you have any question on this report or if you are looking for any specific Segment, Application, Region or any other custom requirements, then Connect with an expert for customization of Report.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19492806

For More Related Reports Click Here :

Automobile Speakers Market In 2022

Manure Collection and Handling Equipment Market In 2022

Modulating Control Valves Market In 2022

See original here:
(New Report) Digital Genome Market In 2022 : The Increasing use in Diagnostics, Agriculture & Animal Research, Personalized Medicine, Drug...

News Release

Monday, January 24, 2022

NIH-funded preclinical study identifies potential therapeutic approach to treat ALS.

Using an experimental drug, researchers were able to suppress a mutated amyotrophic lateral sclerosis (ALS) gene. Studies in mice demonstrate that the therapy could show promise in treating rare, aggressive forms of ALS caused by mutations in the fused in sarcoma (FUS) gene. The study, published in Nature Medicine, was funded in part by the National Institute for Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.

The study models how promising gene-targeting therapies can move expeditiously from pre-clinical development to clinical testing, said Amelie Gubitz, Ph.D., program director at NINDS. There is a desperate need for innovative approaches to treating ALS.

ALS, also known as Lou Gehrigs disease, is a fatal neurological disorder that causes the degeneration of motor neurons in the brain and spinal cord. People with ALS rapidly lose muscle strength and eventually their ability to move, swallow, and breathe. Most cases of ALS are sporadic, but at least 10% of cases are familial, or due to mutations in various genes. Mutations in the gene FUS cause severe forms of ALS, referred to as FUS-ALS, including a rare type that begins in adolescence or young adulthood.

In the study, Neil Shneider, M.D., Ph.D., the Claire Tow Associate Professor of Motor Neuron Disorders and Director of the Eleanor and Lou Gehrig ALS Center at Columbia University, New York City, and his team delayed the onset of motor neuron degeneration in mice by using an antisense oligonucleotide drug designed to silence FUS by blocking cells from making specific proteins. Following encouraging results, they administered the drug to a patient with ALS.

Compared to normal mice, mice with a mutated FUS gene had higher levels of insoluble FUS and other ALS-related proteins in their brains and spinal cords. Mice with higher doses of mutant FUS in motor neurons experienced rapid neurodegeneration that began early in life, much like FUS-ALS patients.

The study establishes a mouse model that is highly disease-relevant, said Dr. Shneider. In mice, we found that FUS toxicity was due to a gain of function and was dose-dependent, suggesting that we could treat FUS-ALS by silencing the FUS gene.

In 2019 Dr. Shneider met an individual with ALS in search of therapies that may help her disease. Inspired by her story, Dr. Shneider teamed up with a pharmaceutical company to develop a personalized therapy designed to target the FUS mutation.

In mice, injecting a single dose of the drug into the ventricles, fluid-filled spaces surrounding the brain, delayed the onset of inflammation and motor neuron degeneration by six months. The drug also knocked down levels of FUS by 50% to 80% in the brain and spinal cord. Following drug administration, insoluble forms of other ALS-associated proteins were also cleared.

Under a compassionate use protocol reviewed by the U.S. Food and Drug Administration, Dr. Shneider administered the drug to the patient it had been designed for. The patient received repeated infusions of the drug into her spinal canal for 10 months. During the treatment, the patients rate of motor function deterioration slowed. The patient tolerated the treatment well and there were no medically adverse effects.

The study is an example of a precision medicine, bench-to-bedside effort, said Dr. Shneider. We began with the mouse model to establish a rationale for the drug, conducted efficacy studies in the mouse, moved the drug into a human, and collected valuable data that was ultimately used to support a larger Phase 3 clinical trial.

Treatment began more than six months after clinical onset, by which time the disease had already significantly advanced. As is typical with juvenile-onset FUS-ALS, the disease progressed rapidly, and the patient died from complications of the disease.

By studying the patients brain and spinal cord tissue, researchers found that the drug silenced FUS throughout the nervous system and reversed the toxic nature of FUS and other disease-related proteins. Compared to tissue from untreated FUS-ALS patients and healthy controls, FUS protein aggregatesa pathological hallmark of this form of ALSwere sparse, suggesting that they may have been cleared by the drug. Tissue samples were provided by the New York Brain Bank of Columbia University.

The protein made from the FUS gene has been shown to be important for various cellular processes. Prior studies in mice suggest that FUS mutations result in the production of an abnormal protein that forms clumps, or aggregates, leading to motor neuron damage. By targeting the faulty gene in a way that suppresses toxic FUS activity, gene silencing products like the antisense oligonucleotide drug could potentially reduce or prevent disease progression.

The results were used to support a clinical trial testing the drug in patients with FUS-ALS (NCT04768972).

This study was supported by grants from the NIH (NS106236), Nancy Perlman, Tom Klingenstein, and the Judith and Jean Pape Adams Charitable Foundation.

NINDSis the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Korobeynikov, V.A., et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nature Medicine, January 24, 2022. DOI: 10.1038/s41591-021-01615-z

###

Continued here:
Silencing a faulty gene may uncover clues to rare forms of ALS - National Institutes of Health

The Soyuz MS-19 crew ship and the Prichal docking module attached to the Nauka multipurpose laboratory module are pictured during an orbital sunset.

The Expedition 66 crew split its research schedule between space botany and life science aboard the International Space Station today.

NASA Flight Engineer Thomas Marshburn started Thursday watering plants growing for the Veggie PONDS study that explores ways to reliably grow vegetables in microgravity. Afterward, the three-time space station visitor verified the operability of the two robotics workstations, located in the U.S. Destiny laboratory module and the cupola, that control the Canadarm2 robotic arm.

Matthias Maurer, flight engineer from ESA (European Space Agency), printed samples from a handheld bioprinter for analysis back on Earth. The samples were printed to investigate how to develop tissues in microgravity to advance personalized medicine on Earth and in space.

The three other NASA Flight Engineers aboard the orbiting lab, Raja Chari, and Kayla Barron, Mark Vande Hei, worked throughout the day on a variety of life support and science maintenance tasks. Chari was on plumbing duty draining and transferring fluids in station tanks. Barron serviced the labs exercise cycle before replacing components in the waste and hygiene compartment, the stations bathroom. Vande Hei processed samples for DNA analysis for the Food Physiology experiment that documents how diet affects a crew members health during a long-term space mission.

The stations commander, Anton Shkaplerov of Roscosmos, was back on exercise research on Thursday exploring how to maximize the effectiveness of working out in weightlessness. Russian Flight Engineer Pyotr Dubrov cleaned up the Zvezda and Poisk modules, returning them to a post-spacewalk configuration following his excursion with Shkaplerov on Jan. 19.

Learn more about station activities by following thespace station blog,@space_stationand@ISS_Researchon Twitter, as well as theISS FacebookandISS Instagramaccounts.

Get weekly video highlights at:http://jscfeatures.jsc.nasa.gov/videoupdate/

Get the latest from NASA delivered every week. Subscribe here:www.nasa.gov/subscribe

Visit link:
Plants, Bioprinting and Orbital Plumbing Fill Crew's Thursday Schedule - NASA

Tackling Seasonal Affective Disorder

MIAMI (PRWEB) January 28, 2022

ClarityX, providers of genetic testing to empower both consumers and physicians, today announced that its at-home genetic tests can aid in finding the appropriate medications for patients combating Seasonal Affective Disorder (SAD). Their testing is able to reveal an individuals genetic profile in order to take the guesswork out of prescribing.

Recent clinical research has shown that depression spikes at the beginning of the new year, with over 10 million Americans struggling with seasonal depression. Seasonal Affective Disorder (SAD) is a type of depression that relates to changes in the seasons. Although the exact cause of SAD is unknown, treatments include light therapy, talk therapy, Vitamin D and antidepressant medications. Unfortunately, the sheer amount of these drugs available on the market make it difficult for healthcare providers to determine which medication will be the most effective for each patient. Additionally, incorrect dosing may interact negatively within a patient.

ClarityX offers genetic test kits that are able to reliably predict a persons response to medication. Pharmacogenetic testing is a type of DNA testing that examines genes for variations that may affect how patients metabolize certain drugs. The insight helps when having to choose between different antidepressants as well as providing physicians information to help with optimal dosing.

Additionally, ClarityX's Mindwell Test is designed to provide answers on how a patient responds to various antidepressants, antipsychotics, anxiolytics, SSNRIs and SSRIs based on their DNA. As genes do not change over time, an individuals Mindwell test results and treatment plan will remain valid and accurate for life. The Mindwell Test covers genetic testing for depression, anxiety, bipolar, ADHD/ADD, OCD, PTSD medications.

Whether someone is experiencing mild SAD or is facing debilitating depression, its important to confront the symptoms. When left untreated, the condition can worsen and infiltrate every aspect of life causing patients to lose interest in their favorite activities, stop maintaining social relationships and neglect their daily obligations, said Andres Benzaquen, President of ClarityX. However, getting the right depression medication is a process of trial and error that can take months. ClarityX helps cut the guesswork out of the process - especially as more and more patients are searching for personalized, precise medication healthcare. In the near future, you won't be prescribed medications without a pharmacogenetic test.

Testing happens in a quick three step process. First, the patient clicks the "Get Started" button torequest a ClarityX test. Once a patient has received and activated their kit, they perform a simple cheek swab. The sample is then returned in the provided pre-paid envelope. Patients receive their personalized report online in their ClarityX patient portal and the results can easily be shared with their doctors.

The days of going back and forth to your physician just to find the right medications are over. "Were at the beginning of a growing shift towards the at-home medically actionable, test market., adds Benzaquen. . In a time when mental Health is a growing problem - and has been exacerbated during Covid - precision medicine is the future of healthcare. Our genetic tests can help to take the guesswork out of your medications,

Whether patients are looking for a new medication or have been recently diagnosed with SAD, pharmacogenetics can help find the optimal treatment to empower people to take control of their health, happiness and overall well-being.

For more information, please visit http://www.clarityxdna.com, Email: abenz@clarityxdna.comor call 800-921-8957 for more information.

ClarityX believes in taking the guesswork out of your healthcare. We Believe that one size does not fit all, when it comes to your medication or treatments. Individualized personal medicine is the future of healthcare.

ClarityX direct to consumer genetic testing empowers both patients and physicians. We deliver on that promise everyday by helping patients with convenient, easily accessible in-home testing options.

Share article on social media or email:

See the original post:
ClarityX DNA: The Key to Tackling Seasonal Affective Disorder - PR Web

DUBLIN--(BUSINESS WIRE)--The "High Performance Computing Market by Component, Infrastructure, Services, Price Band, HPC Applications, Deployment Types, Industry Verticals, and Regions 2022 - 2027" report has been added to ResearchAndMarkets.com's offering.

The High Performance Computing market includes computation solutions provided either by supercomputers or via parallel processing techniques such as leveraging clusters of computers to aggregate computing power.

HPC is well-suited for applications that require high performance data computation and analysis such as high frequency trading, autonomous vehicles, genomics-based personalized medicine, computer-aided design, deep learning, and more. Specific examples include computational fluid dynamics, simulation, modeling, and seismic tomography.

This report evaluates the HPC market including companies, solutions, use cases, and applications. Analysis includes HPC by organizational size, software and system type, server type, price band, and industry verticals.

The report also assesses the market for integration of various artificial intelligence technologies in HPC. It also evaluates the exascale-level HPC market including analysis by component, hardware type, service type, and industry vertical.

Select Report Findings:

High Performance Computing (HPC) may be provided via a supercomputer or via parallel processing techniques such as leveraging clusters of computers to aggregate computing power. HPC is well-suited for applications that require high performance data computation such as certain financial services, simulations, and various R&D initiatives.

The market is currently dominated on the demand side by large corporations, universities, and government institutions by way of capabilities that are often used to solve very specific problems for large institutions. Examples include financial services organizations, government R&D facilities, universities research, etc.

However, the cloud-computing based "as a Service" model allows HPC market offerings to be extended via HPC-as-a-Service (HPCaaS) to a much wider range of industry verticals and companies, thereby providing computational services to solve a much broader array of problems. Industry use cases are increasingly emerging that benefit from HPC-level computing, many of which benefit from split processing between localized devices/platforms and HPCaaS.

In fact, HPCaaS is poised to become much more commonly available, partially due to new on-demand supercomputer service offerings, and in part as a result of emerging AI-based tools for engineers. Accordingly, up to 54% of revenue will be directly attributable to the cloud-based business model via HPCaaS, which makes High-Performance Computing solutions available to a much wider range of industry verticals and companies, thereby providing computational services to solve a much broader array of problems.

One of the challenge areas identified is low utilization but (ironically) also high wait times for most supercomputers. Scheduling can be a challenge in terms of workload time estimation. About 23% of jobs are computationally heavy and 37% of jobs cannot be defined very well in terms of how long jobs will take (within a 3-minute window at best). In many instances, users request substantive resources and don't actually use computing time.

Key Topics Covered:

High Performance Computing Market Dynamics

High Performance Computing Market Analysis and Forecasts

High Performance Computing Company Analysis

High Performance Computing Market Use Cases

Conclusions and Recommendations

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/fim7bo

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Go here to see the original:
Global High Performance Computing Market 2022-2027: AI, IoT, and 5G will be Major Drivers for HPC Growth as they Facilitate the Need to Process Vast...

Since 2015, groups of medical students at the Northwestern Feinberg School of Medicine in Chicago have been working diligently to answer a single question: How can we improve healthcare at the system level?

Medical students have and always will be expected to provide personalized, high-quality care to their patients. But amid all the studying, rotations, research and clinical volunteering, there is another area of professional growth and healthcare activism emerging that allows students to promote broader change across the healthcare system: community health consulting.

A group of students at Feinberg, now more than 50 in any given year, have been providing pro-bono strategy consulting services to community clinics and healthcare not-for-profits for more than six years as members of Second Opinions, a 501(c)(3) not-for-profit student organization founded by a trio of management consultants-turned-physicians. Second Opinions aims to promote system-level change in healthcare by pairing medical students with local healthcare organizations to support a variety of administrative and strategic initiatives.

Groups of four to five Second Opinions members work together on discrete projects for four months at a time, tackling problems in areas ranging from clinical workflow analysis to healthcare and not-for-profit economics. Current projects include helping one local community clinic improve its mammogram referral network and assisting a second clinic in the creation of an equitable sliding scale payment system for uninsured patients. While our projects are based on set timelines, we establish follow-up procedures in which we continue working with clients on emerging issues. This continuity-of-care approach is crucial across all levels of healthcare and is what drew many of us to medicine in the first place.

Download Modern Healthcares app to stay informed when industry news breaks.

Second Opinions shines brightest in its work to improve outcomes for underserved populations. Amid rising costs and legislative volatility in healthcare, Free and Charitable Clinics (FCCs) as well as Federally Qualified Health Centers (FQHCs) have led the way in providing accessible care to underinsured or uninsured Americans. To help them overcome their greatest obstacles, quantifying community impact and obtaining funding, our group recently created a reimbursement valuation tool to determine the monetary and quality-adjusted life years (QALY) values of services provided by free clinics as well as the value of appropriately averted emergency department visits.

The impact of our valuation tool started locally but soon gained national traction. First, we presented to the Illinois Association of Free and Charitable Clinics, a cluster of just over 40 FCCs. Soon, our team was presenting to board members of the National Association of Free and Charitable Clinics, an organization of over 1,400 FCCs. This information has important implications for how healthcare resources get distributed, and our work quantifying averted downstream costs and disease strengthened the case for investing in these providers.

System-level change does not have to occur on a national scale. The work can start by aiding a local women's health clinic in the transition from paper records to an efficient electronic health record system so that more underrepresented Chicagoans can be seen each day. It can be performing community health needs assessments for neighboring clinics that operate in Chicago's West and South Sides, or even helping our own institution expand the reach of its pediatrics mobile health program.

Through experiences like this, our medical student members learn how to effect change on system-level healthcare issues and leave empowered to help both individual patients and the systemequipped to care for the forest and the trees. The problems we face are complex and open-ended, and our members are challenged to find ways to measure system performance and enact change through policy, workflow improvements, and clinical protocols that benefit entire patient populations, particularly underserved ones. This is a tall order, but as medical students, our advantage is that we are always intimately observing from the inside with a fresh perspective and a passion for creative innovation.

Our members grew up in an era marked by healthcare disparities and inefficiencies. The dysfunction of our American healthcare system is broadcast to us throughout medical school. We are ready to innovate, and we believe physicians should always have a seat at the table when it comes to improving the healthcare system and operating the business of healthcare. Our members are eager to provide actionable recommendations and create solutions to problems that burden the same underrepresented patients we hope to care for in clinics and hospitals throughout our careers. We also realize we have much to learn. Our members remain humble, ready to begin each project by listening for as long as it takes to adequately understand the scope of the issue at hand. Most of all, our members are creativeunafraid to invent solutions where there is no precedent to guide them.

We encourage medical trainees across the country to join in our efforts to promote community health through strategy work. There is space for anyone who is dedicated to community health to help, and we are excited to support others with this important work. System-level change is difficult but powerful, so help where you are needed and get creative. And if you need a Second Opinions consult, you know who to page.

Drs. Cecil Qiu, Liz Nguyen and Benjamin Peipert contributed to this article. All graduated from Northwestern University Feinberg School of Medicine. Qiu is a resident at Johns Hopkins University School of Medicine, Nguyen is a resident at Stanford University School of Medicine, and Peipert is a resident at Duke University School of Medicine.

Read the rest here:
A different kind of consult: pro-bono community health consulting by med students - Modern Healthcare

Advanced four wholly owned and internally developed programs into clinical development

See the rest here:
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that it will deliver a platform presentation and two poster presentations at the 18th Annual WORLDSymposium™, a research conference dedicated to lysosomal storage diseases, taking place February 7 – 11, 2022 in San Diego, California. The presentations will include updated data from the Company’s ongoing Phase 1/2 MARVEL-1 clinical trial evaluating FLT190 for the treatment of patients with Fabry disease and the clinical trial design for GALILEO-1, a Phase 1/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1.

See the rest here:
Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™

SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) third quarter after the market closes on Thursday, February 10, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter’s financial results and report on business progress.

Originally posted here:
23andMe to Report FY2022 Third Quarter Financial Results

Participants include a syndicate of existing and new shareholdersContributes to total of $10.1 million in new equity financing for January, 2022

Continued here:
Vaccinex Announces $6.6 Million Private Placement

John W. Smither Appointed to its Board of Directors and Named Audit Committee Chair

More here:
Applied Molecular Transport Announces Board Appointments

MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive commercial distribution agreement with Athens-based BIOKOSMOS S.A. (BIOKOSMOS) for Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) for the Greek and Cypriot markets.

Read the original here:
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (“ODD”) to evorpacept, a next-generation CD47 blocker, for the treatment of patients with gastric cancer and gastroesophageal junction cancer (collectively “GC”).

More here:
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction...

The companies will continue with their exclusive agreements, including for commercialization of their current portfolio The companies will continue with their exclusive agreements, including for commercialization of their current portfolio

View post:
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner

See the article here:
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV...

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the SVB Leerink 11th Annual Global Healthcare Conference 2022. The conference is being conducted in a virtual format and the presentation will take place on Thursday, Feb. 17, 2022 at 8:40 a.m. ET.

Originally posted here:
Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022